A Market Frankenstein: What AI Gambles and Egg Farms Tell Us About Wall Street's LeftoversGlobal Report·Jul 22 at 04:18 AMTROO+5.15%EOSER0.00%
Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data AdvancesTip Ranks·Jul 10 at 09:45 AMMTVA0.00%
MetaVia says all active patients reach highest target doses in DA-1726 obesity Phase 1 Part 3 studyPUBT·Jul 9 at 07:33 AMMTVA0.00%
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor ForumUnusual Whales·Jun 17 at 07:33 AMMTVA0.00%
MetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price TargetTip Ranks·Jun 12 at 02:55 PMMTVA0.00%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jun 9 at 07:05 AMBJDX+5.77%ICCM+0.35%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 8 at 07:06 AMNOTV0.00%ADTX-13.33%
MetaVia presents ADA 2026 data: DA-1726 shows up to 9.1% weight loss; vanoglipel combos show synergistic metabolic and liver benefitsTradingView·Jun 8 at 08:03 AMMTVA0.00%
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential | MTVA Stock NewsStockTitan·Jun 7 at 11:31 PMMTVA0.00%
